The impact of capping health system cost savings on the projected cost-effectiveness of etranacogene dezaparvovec compared with factor IX prophylaxis for the treatment of hemophilia B.

Author List

Sarker J, Tice JA, Rind DM, Pearson SD, Walton SM

Publication

Journal of managed care & specialty pharmacy

Publication ID (Profile URL)

https://researcherprofiles.org/profile/532621221

Publication Year

2024

PubMed ID

39088338

Publication Title

Sarker J, Tice JA, Rind DM, Pearson SD, Walton SM. The impact of capping health system cost savings on the projected cost-effectiveness of etranacogene dezaparvovec compared with factor IX prophylaxis for the treatment of hemophilia B. J Manag Care Spec Pharm. 2024 Aug; 30(8):868-872.